Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood

ConditionsAneurysm, Ruptured Hyperglycemia Hydrocephalus

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIsabel Hostettler

About this trial

The goal of this study is to confirm the association of early increased glucose levels in cerebro-spinal fluid (CSF) and ventriculo-peritoneal-shunt (VPS)-dependency also evaluating the influence of blood glucose on VPS dependency in patients suffering from an aneurysmal subarachnoid haemorrhage (aSAH). The main questions we aim to answer are:

* Is there an association of glucose levels on VPS dependency in patients requiring extra-ventricular-drain (EVD) placement for aSAH? * In addition, if there is, what is the influence the course of glucose levels has on VPS dependency?

Glucose levels in CSF and serum will be measured on admission, or in case of CSF, upon EVD placement. Glucose in CSF will then be measured every day until EVD removal together with serum glucose. Follow-up will be conducted in person after 3 and 6 months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years old and older

Hospital admission due to an aneurysmal subarachnoid haemorrhage (radiological confirmation needed)

Disqualifiers

Younger than 18 years old

Non-aneurysmal subarachnoid haemorrhage (eg. trauma, perimesencephalic subarachnoid haemorrhage, mycotic or flow-associated aneurysms)

Previous enrolment into the current study

Trial population

Patients admitted with aneurysmal subarachnoid haemorrhage

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Cerebrospinal Fluid (CSF) Sample
Diagnostic test
Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
Blood Serum Sample
Diagnostic test
Samples for glucose in blood serum will be completed every day, for the first 14 days.

Treatment groups

160 Participants

are divided into 1 treatment group

Group A: aSAH Patients2 interventions

Trial outcomes

Primary outcomes

Ventriculo-peritoneal shunt (VPS) dependency

Glucose levels in patients requiring EVD/LD placement for aSAH and its influence on VPS dependency.

Time frame

6 months

Secondary outcomes

Modified Ranking Scale (mRS)

Modified Ranking Scale 0-6 where 0 means no symptoms and 6 death (adjusting for VPS dependency) in aSAH patients requiring EVD/LD placement

Time frame

6 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Isabel Hostettler

Lead sponsor

Cantonal Hospital of St. Gallen

Sponsor institution

Kantonsspital Aarau

Collaborator

University Hospital, Basel, Switzerland